Search
- Oct 19, 2023
Action Potential Venture Capital's Imran Eba describes the field of bioelectronic medicine
Imran Eba explains the idea of aiming to treating any disease by stimulating or blocking nerve signals, an investment focus of his firm.
Also look for unique social pages for BiotechTV U.
#1. Ultragenyx's Emil Kakkis on Angelman syndrome data, rare disease treatment modalities, and more
#2. The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
#3. Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more
#4. Verve Therapeutics' CEO on today's gene editing clinical trial pause
#5. Daphne Zohar on becoming the CEO of Seaport Therapeutics and a $100M series A